Gubra ASSTU:PI3 -3.11%56 Current Ratio is 13.63 as of Dec. 2025, which is 565% above its 10-year median of 2.05. GuruFocus rates STU:PI3 with a GF Score™ of 56/100 and a GF Value™ of €381.59 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Gubra AS ranks better than 84.32% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Gubra AS's current ratio for the quarter that ended in Dec. 2025 was 13.63.
Gubra AS has a current ratio of 13.63. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Gubra AS's Current Ratio or its related term are showing as below:
STU:PI3'
s Current Ratio Range Over the Past 10 Years
Min: 1.72 Med: 2.05 Max: 13.63
Current: 13.63
During the past 7 years, Gubra AS's highest Current Ratio was 13.63. The lowest was 1.72. And the median was 2.05.
STU:PI3's Current Ratio is ranked better than 84.32% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs STU:PI3: 13.63
Gubra AS (STU:PI3) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Gubra AS Current Ratio Related Terms
Gubra AS Current Ratio Historical Data
* Premium members only.
The historical data trend for Gubra AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PI3 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Gubra AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Gubra AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (STU:PI3) has a Current Ratio of 13.63 as of Dec. 2025. This is 565% above median its historical median of 2.05. Over the past decade, Gubra AS's Current Ratio has ranged from 1.72 to 13.63. According to the industry distribution chart, Gubra AS ranks #222 out of 1416 companies in the Biotechnology industry, placing it in the top 15.7%.
Is Gubra AS's Current Ratio too high?
Gubra AS's current Current Ratio of 13.63 is 565% above median its 10-year median of 2.05. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 13.63. The Biotechnology industry median Current Ratio is 3.89. Gubra AS's value of 13.63 is 250.8% above this industry median. Based on the distribution chart, Gubra AS ranks #222 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #222 out of 1416 companies for Current Ratio. This places Gubra AS in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Gubra AS's value of 13.63 is 250.8% above this benchmark. Historically, Gubra AS's own Current Ratio has ranged from 1.72 to 13.63 over the past decade. While the company's 10-year median is 2.05 vs. the industry median of 3.89, Gubra AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current Current Ratio of 13.63 is 250.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Current Ratio is 13.63, which is 565% above median its own 10-year median of 2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (STU:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €381.59, compared to a current price of €43.04 — trading 88.7% below its estimated fair value. The current Current Ratio is 13.63, which is 565% above median its 10-year median of 2.05 and 250.8% above the Biotechnology industry median of 3.89. Gubra AS's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Gubra AS (STU:PI3), the current Current Ratio is 13.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (STU:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €43.04 is trading 88.7% below its estimated GF Value™ of €381.59.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for STU:PI3:
Current Ratio: 13.63 (565% above median its 10-year median of 2.05)
GF Value™: €381.59 vs. price of €43.04 (88.7% below fair value)
Industry Position: 250.8% above the Biotechnology median (#222 of 1416)
No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
56GF Score
Get the complete analysis for STU:PI3
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PI3 has been successfully added to your 
